Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study

被引：0
作者：
Qi Wei
Taibing Deng
Junhua Wu
Hao Zeng
Chang Qi
Sihan Tan
Yuanyuan Zhang
Qin Huang
Xin Pu
Weiguo Xu
Weimin Li
Panwen Tian
Yalun Li
机构：
[1] Sichuan University,Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease
[2] Sichuan University,related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital
[3] Guang ’an People’s Hospital,Lung Cancer Center/Lung Cancer Institute, West China Hospital
[4] Mianyang Central Hospital,Pulmonary and Critical Care Medicine
[5] University of Electronic Science and Technology of China,Respiratory and Critical Care Medicine, School of Medicine
来源：
BMC Cancer | / 24卷
关键词：
Non-small cell lung cancer; Malignant pleural effusion; Immunotherapy; Chemotherapy; Efficacy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 191 条
[1]  
Zamboni MM(2015)Important prognostic factors for survival in patients with malignant pleural effusion BMC Pulm Med 15 29-54
[2]  
da Silva CT(2017)US hospitalizations for malignant pleural effusions: data from the 2012 National Inpatient Sample Chest 151 845-76
[3]  
Baretta R(2012)Pleural effusion in lung cancer: more questions than answers Respiration 83 367-41
[4]  
Cunha ET(2021)Intrapleural injection of Anti-PD1 antibody: a Novel Management of Malignant Pleural Effusion Front Immunol 12 760683-9
[5]  
Cardoso GP(2017)Management of malignant pleural effusion: challenges and solutions Cancer Manag Res 9 229-9
[6]  
Taghizadeh N(2012)Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer J Thorac Oncol 7 1485-8
[7]  
Fortin M(2021)Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): the pluie study Lung Cancer 155 114-51
[8]  
Tremblay A(2020)Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study Invest New Drugs 38 211-8
[9]  
Froudarakis ME(2018)Pembrolizumab plus Chemotherapy for squamous non-small-cell Lung Cancer N Engl J Med 379 2040-46
[10]  
Li X(2021)Long-term overall survival from KEYNOTE-021 cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC J Thorac Oncol 16 162-14
12345678910